121 related articles for article (PubMed ID: 11182836)
1. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial.
Weissman NJ; Panza JA; Tighe JF; Gwynne JT
Ann Intern Med; 2001 Feb; 134(4):267-73. PubMed ID: 11182836
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
J Am Coll Cardiol; 1999 Dec; 34(7):2088-95. PubMed ID: 10588229
[TBL] [Abstract][Full Text] [Related]
3. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
[TBL] [Abstract][Full Text] [Related]
4. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.
Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL
Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835
[TBL] [Abstract][Full Text] [Related]
5. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
[TBL] [Abstract][Full Text] [Related]
6. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
[TBL] [Abstract][Full Text] [Related]
8. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
[TBL] [Abstract][Full Text] [Related]
9. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.
Wee CC; Phillips RS; Aurigemma G; Erban S; Kriegel G; Riley M; Douglas PS
Ann Intern Med; 1998 Dec; 129(11 Pt 1):870-4. PubMed ID: 9867728
[TBL] [Abstract][Full Text] [Related]
10. Dexfenfluramine and heart-valve regurgitation in Chinese patients with type 2 diabetes.
Ko GT; Chan HC; Chow CC
Hong Kong Med J; 2003 Aug; 9(4):243-6. PubMed ID: 12904610
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine.
Roldan CA; Gill EA; Shively BK
Am J Cardiol; 2000 Sep; 86(5):535-9. PubMed ID: 11009272
[TBL] [Abstract][Full Text] [Related]
12. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine.
Shively BK; Roldan CA; Gill EA; Najarian T; Loar SB
Circulation; 1999 Nov; 100(21):2161-7. PubMed ID: 10571975
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
16. Specificity of Doppler echocardiography for the assessment of changes in valvular regurgitation: comparison of side-by-side versus serial interpretation.
Weissman NJ; Panza JA; Tighe JF; Perras ST; Kushner H; Gottdiener JS
J Am Coll Cardiol; 2001 May; 37(6):1614-21. PubMed ID: 11345374
[TBL] [Abstract][Full Text] [Related]
17. Operation for anorexigen-associated valvular heart disease.
Caccitolo JA; Connolly HM; Rubenson DS; Orszulak TA; Schaff HV
J Thorac Cardiovasc Surg; 2001 Oct; 122(4):656-64. PubMed ID: 11581595
[TBL] [Abstract][Full Text] [Related]
18. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB
Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711
[TBL] [Abstract][Full Text] [Related]
19. Natural history of valvular regurgitation using side-by-side echocardiographic analysis in anorexigen-treated subjects.
Klein AL; Griffin BP; Grimm RA; Rodriguez LL; Sallach JA; Morehead AJ
Am J Cardiol; 2005 Dec; 96(12):1711-7. PubMed ID: 16360362
[TBL] [Abstract][Full Text] [Related]
20. Severe mitral valve regurgitation associated with dexfenfluramine use.
Aurigemma GP; Ronen A; Cuénoud H; Folland ED; Meyer TE
Cardiology; 2002; 98(4):215-7. PubMed ID: 12566653
[No Abstract] [Full Text] [Related]
[Next] [New Search]
